Ethan Shin is a life science venture capital investor with extensive experience in various roles within the industry. They served as a Board Observer at Arvelle Therapeutics from 2019 to 2021 and were a Director on the Board at Bridge Biotherapeutics, Inc. from 2017 to 2018. Currently, Ethan holds multiple positions, including Managing Director at KB Investment and Board Observer at Pathalys Pharma, Bright Peak Therapeutics, and several other companies. Ethan holds a Doctor of Pharmacy from the University of Illinois Chicago and a Bachelor of Science in Chemistry from Emory University.
This person is not in the org chart
This person is not in any teams
This person is not in any offices